Immune checkpoint inhibitors (ICIs), anti-programmed cell death 1 receptor (PD-1), anti-programmed cell death ligand (PD-L1), or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) have demonstrated significant anti-tumor activity, with tolerable safety profiles and durable responses in various neoplasia [4-6]. This evidence concerns the gene CTLA4 and neoplasm.